LUND, SWEDEN--(Marketwire - April 23, 2009) -
* Laquinimod -- Fast Track status granted by the FDA * 57-57 -- planning of exploratory study in progress * RhuDex™ -- preclinical tests under way * ANYARA -- Phase III trial proceeding as planned * TASQ -- safety profile assessed by independent international expert group, Phase II trial proceeding as planned * Net sales SEK 2.2 M (3.2) * Operating loss SEK 63.7 M (loss: 52.2) * Loss after tax SEK 62.2 M (loss: 52.7) * Loss per share for the period was SEK 1.21 (loss 1.11)
For further information, please contact: Tomas Leanderson President and CEO Tel: +46 (0)46-19 20 95 Göran Forsberg VP Investor Relations & Business Development Tel: +46 (0)46-19 11 54 Hans Kolam CFO Tel: +46 (0)46-19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227) PO Box 724, 220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
Active Biotech AB Interim report Jan-March 2009: http://hugin.info/1002/R/1307424/300945.pdf
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
